证券代码：600668 证券简称：尖峰集团 公告编号：2024-015 浙江尖峰集团股份有限公司 关于召开 2023 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 会议召开时间：2024 年 05 月 16 日(星期四) 下午 15:00-16:00 会议召开地点：上海证券交易所上证路演中心（网址： （二） 会议召开地点：上证路演中心 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 05 月 09 日(星期四) 至 05 月 15 日(星期三)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 jfjtsmh@126.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 浙江尖峰集团股份有限公司（以下简称"公司"）已于 2024 年 4 月 30 日发 布公司 2023 年度报告，为便于广大投资者更全面深入地了解公司 2023 年度经营 成果、财务状况，公司计划于 202 ...

浙江尖峰集团股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：600668 证券简称：尖峰集团 编号：临 2024-014 重要内容提示： 近日，浙江尖峰集团股份有限公司（以下简称"本公司"）的全资子公司浙江 尖峰药业有限公司（以下简称"尖峰药业"）收到国家药品监督管理局核准签发的 他氟前列素滴眼液《药品注册证书》（证书编号：2024S00682），现将相关情况公 告如下： 一、化学仿制药的基本情况 药品名称：他氟前列素滴眼液 剂型：眼用制剂 规格：0.0015%（2.5ml: 37.5μg） 申请事项：药品注册（境内生产） 注册分类：化学药品 4 类 药品上市许可持有人：浙江尖峰药业有限公司 生产企业名称：浙江尖峰药业有限公司 1 本次尖峰药业获得他氟前列素滴眼液《药品注册证书》，标志着尖峰药业 具有进行该药品生产、销售的资格，将进一步丰富尖峰药业的产品种类， 有助于提升公司医药业务的竞争力。 风险提示：由于医药产品具有高科技、高风险、高附加值的特点，不仅 药品的 ...

Financial Performance - The company's operating revenue for 2023 was CNY 289,336.89 million, a decrease of 18.73% compared to CNY 356,039.41 million in 2022[21]. - The net profit attributable to shareholders for 2023 was CNY 9,375.62 million, down 67.41% from CNY 28,772.04 million in 2022[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 6,493.37 million, a decrease of 41.65% from CNY 11,127.43 million in 2022[21]. - The net cash flow from operating activities for 2023 was CNY 4,242.89 million, a significant decline of 88.93% from CNY 38,333.03 million in 2022[21]. - The net assets attributable to shareholders at the end of 2023 were CNY 510,949.13 million, a decrease of 1.47% from CNY 518,560.53 million at the end of 2022[21]. - Total assets at the end of 2023 were CNY 704,727.97 million, down 3.73% from CNY 732,060.34 million at the end of 2022[21]. - The company's basic earnings per share decreased by 67.41% to CNY 0.2725 in 2023 compared to CNY 0.8362 in 2022[22]. - The company's total operating revenue for 2023 was CNY 2.893 billion, down 18.73% from the previous year[28]. - The company's net profit attributable to the parent company was 93.76 million RMB, down 67.41% compared to the previous year[43]. - The company's main business revenue was 2.765 billion RMB, with a main business cost of 2.174 billion RMB, resulting in a gross margin of 21.39%[47]. Industry Challenges - The company faced a 0.7% decline in total cement production in the industry, reaching the lowest level in a decade[27]. - The cement industry faced severe challenges due to increased competition, high raw material costs, and a downturn in the real estate sector, leading to a significant shrinkage in industry profits[31]. - The real estate development investment in China for 2023 was CNY 11.09 trillion, down 9.6% year-on-year, impacting cement demand[31]. Pharmaceutical Segment - The pharmaceutical segment achieved significant progress in innovation and R&D, with seven new products approved for market, including esomeprazole magnesium and valsartan amlodipine tablets[30]. - The company’s pharmaceutical products have expanded to include a new class of anti-tumor drug, JFAN-1001, which has completed Phase I clinical trials and received FDA approval for clinical trials in October 2023[30]. - The pharmaceutical segment's revenue was 987.51 million RMB, down 29.61% year-on-year, with a gross margin of 24.46%[47]. - The company is focusing on the development of pediatric and geriatric medications, with ongoing research in various dosage forms[81]. Research and Development - The company has over 20 R&D projects at various stages, including new drug JFAN-1001 completing Phase I clinical trials[40]. - The company is implementing a full industry chain upgrade strategy for intermediates, raw materials, and formulations[40]. - The company is focusing on innovation and drug clinical value, actively engaging in consistency evaluations and adjusting marketing strategies to align with national medical policies[72]. - The company has set performance guidance for the upcoming fiscal year, aiming for a growth rate of approximately 10% in revenue[75]. Environmental Initiatives - The company is committed to reducing operational risks through lean production and strengthening internal management and process technology[72]. - The company is committed to achieving ultra-low emissions standards for its cement production lines by the end of the year through advanced technology upgrades[111]. - The company has invested ¥5,240.10 million in environmental protection during the reporting period[163]. - The company has implemented various energy-saving and emission-reduction measures, resulting in a significant decrease in carbon emissions during the reporting period[178]. Governance and Compliance - The company held 6 board meetings and 2 shareholder meetings during the reporting period, ensuring compliance with corporate governance regulations[121]. - The company has revised its internal control systems in accordance with relevant laws and regulations to enhance governance and operational standards[123]. - The company has a performance evaluation and incentive mechanism linking the remuneration of directors and senior management to company performance[124]. - The company has not reported any significant deficiencies in its internal control systems during the reporting period, indicating effective governance[159]. Future Outlook - Future outlook includes a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[129]. - The company plans to enhance its international development strategy to improve product quality and competitiveness[72]. - The company aims to expand its market presence by increasing coverage in grassroots communities and the OTC market[72]. - The company plans to continue expanding its cement production capacity and explore new projects in resource-rich areas[106].

证券代码：600668 证券简称：尖峰集团 公告编号：2024-013 浙江尖峰集团股份有限公司 二、报告期内分产品经营数据 单位：万元 币种：人民币 | | | | 主营业务收入 | | | | 主营业务成本 | | 毛利率 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 产品 | 2024 | 年 | 2023 | 年 | 增长率 | 2024 年 | 2023 年 | 增长率 | 2024 | 2023 | | | | | | | | | | | 年 | 1-3 | 年 1-3 | 增减百分点 | | | 1-3 | 月 | 1-3 | 月 | （%） | 1-3 月 | 1-3 月 | （%） | | | | | | | | | | | | | | 月（%） | 月（%） | | 行业 主营业务收入 主营业务成本 毛利率 2024 年 1-3 月 2023 年 1-3 月 增长率 （%） 2024 年 1-3 月 2023 年 1-3 月 增长率 （%） 2024 年 1-3 月（%） ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 601.67 million, a decrease of 0.93% compared to the same period last year[5]. - Net profit attributable to shareholders was CNY 2.43 million, down 89.51% year-on-year, primarily due to a decline in product gross margin[5][8]. - The basic and diluted earnings per share were both CNY 0.0071, reflecting a decrease of 89.51% compared to the previous year[5][8]. - The company reported a significant decline in net profit due to reduced gross margins, impacting overall profitability[8]. - The company reported a net profit margin of -1.43% for Q1 2024, compared to a net profit margin of 0.82% in Q1 2023[18]. - In Q1 2024, the company reported a net profit of CNY 1,605,059.71, a significant decrease of 91% compared to CNY 17,846,527.06 in Q1 2023[19]. - The company's operating profit was CNY 11,703,054.11, a decline of 53% from CNY 24,851,658.10 in Q1 2023[19]. - The total comprehensive income for the period was CNY 5,615,076.93, a decrease of 60% compared to CNY 14,106,650.65 in Q1 2023[20]. Cash Flow and Assets - The net cash flow from operating activities was CNY -10.12 million, indicating a decrease in cash inflow from operations[5][8]. - The net cash flow from operating activities was negative at CNY -10,124,178.44, worsening from CNY -7,741,386.39 in Q1 2023[23]. - Cash and cash equivalents decreased to RMB 184,563,650.54 from RMB 211,278,795.28 at the end of 2023[13]. - The cash and cash equivalents at the end of the period stood at CNY 153,823,798.93, a decrease from CNY 277,498,034.84 at the end of Q1 2023[24]. - Current assets as of March 31, 2024, totaled RMB 1,127,553,925.02, an increase from RMB 1,100,430,619.82 at the end of 2023[13]. - Total assets at the end of Q1 2024 were CNY 7,080.23 million, an increase of 0.47% from the end of the previous year[6]. - Total assets increased to RMB 7,080,232,036.90 from RMB 7,047,279,717.07 at the end of 2023[14]. - Total liabilities as of March 31, 2024, were RMB 1,629,844,703.41, compared to RMB 1,578,751,464.77 at the end of 2023[15]. Shareholder Information - Shareholders' equity attributable to the company was CNY 5,113.77 million, a slight increase of 0.08% from the previous year-end[6]. - The company's equity attributable to shareholders was RMB 5,113,773,661.26, slightly up from RMB 5,109,491,340.32 at the end of 2023[15]. - The total number of common shareholders at the end of the reporting period was 35,661[9]. Operating Costs and Expenses - Total operating costs for Q1 2024 were RMB 608,529,424.76, an increase of 0.28% from RMB 605,839,763.70 in Q1 2023[18]. - Operating costs included RMB 478,541,811.90 in cost of goods sold, up from RMB 469,877,792.37 in the previous year[18]. - Research and development expenses decreased to CNY 20,575,078.73, down 16% from CNY 24,512,620.36 year-over-year[19]. - The company reported a total tax expense of CNY 9,721,245.51, an increase from CNY 8,039,865.68 in the previous year[19]. Non-Recurring Items - Non-recurring gains and losses amounted to CNY 8.00 million, with government subsidies contributing CNY 10.24 million[7][8]. - The company achieved an investment income of CNY 5,336,114.93, down 64% from CNY 14,706,111.76 in the previous year[19]. - The weighted average return on equity was 0.05%, a decrease of 0.40 percentage points compared to the previous year[5].

证券代码：600668 证券简称：尖峰集团 编号：临 2024-006 浙江尖峰集团股份有限公司 关于子公司获得药品补充申请批准通知书的公告 一、药品基本情况 药品名称：注射用盐酸头孢甲肟 剂型：注射剂 规格：0.25g、0.5g、1.0g（按 C₁₆H₁₇N₉O₅S₃计） 注册分类：化学药品 原药品批准文号：国药准字 H20041145、国药准字 H20041146、国药准字 1 本次浙江尖峰药业有限公司（以下简称"尖峰药业"）获得注射用盐酸头孢 甲肟的《药品补充申请批准通知书》， 标志着该药品已通过仿制药质量和疗 效一致性评价（以下简称"仿制药一致性评价"）。 风险提示：由于医药产品具有高科技、高风险、高附加值的特点，不仅药品 的前期研发及研制、报批到投产的周期长、投入大、环节多，而且药品的生 产和销售也容易受到国家政策、市场环境变化等因素影响，具有较大不确定 性。敬请广大投资者注意投资风险。 H20041147 药品注册标准编号：YBH07522024 上市许可持有人：浙江尖峰药业有限公司 生产企业名称：浙江尖峰药业有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗 ...

证券简称：尖峰集团 证券代码：600668 编号：临 2024-005 二〇二四年四月十七日 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江尖峰集团股份有限公司（以下简称"公司"）第十一届监事会职工监事 庞雄先生于 2024 年 4 月 16 日因病医治无效不幸去世。 庞雄先生在公司任职期间，勤勉尽职、恪尽职守，忠实地履行了监事应尽的 职责和义务。公司对庞雄先生的去世表示沉痛哀悼，并向其家属致以深切慰问。 因庞雄先生去世，公司职工监事的比例低于三分之一，公司将根据相关法律 法规和《公司章程》等相关规定，尽快完成职工监事的补选，并及时履行信息披 露义务。 特此公告 监事会 浙江尖峰集团股份有限公司 关于职工监事去世的公告 浙江尖峰集团股份有限公司 ...

证券简称：尖峰集团 证券代码：600668 编号：临 2024-004 浙江尖峰集团股份有限公司 关于为全资子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 ● 本次担保金额及已实际为其提供的担保余额：本次为尖峰药业提供担保金额 为3,000万元；除本次担保外，本公司没有为其提供担保。 ● 本次担保是否有反担保：无 ● 对外担保逾期的累计数量：无 ● 特别风险提示：尖峰药业资产负债率超过70%，敬请投资者充分关注担保风险。 一、担保情况概述 2024年2月19日，本公司与中国民生银行股份有限公司金华分行（以下简称 "民生银行金华分行"）签署了《保证合同》（以下简称"本合同"），本公司为全 资子公司尖峰药业的民生银行金华分行的短期流动资金贷款3,000万元提供连带 责任保证。 根据本公司 2023 年 4 月 14 日召开的第十一届董事会第 12 次会议和 2023 年 5 月 18 日召开的 2022 年年度股东大会审议通过的《关于为控股子公司提供 担保的议案》，本公司对尖峰药业设定担保额度为 2 ...

证券代码：600668 证券简称：尖峰集团 编号：临 2024-002 浙江尖峰集团股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 近日，浙江尖峰集团股份有限公司（以下简称"本公司"）的全资子公司浙 江尖峰药业有限公司（以下简称"尖峰药业"）的控股子公司浙江尔婴药品有限 公司（以下简称"尔婴公司"）收到国家药品监督管理局核准签发的对乙酰氨基 酚栓《药品注册证书》（证书编号：2024S00084），现将相关情况公告如下： 一、药品的基本情况 药品名称：对乙酰氨基酚栓 剂型：栓剂 规格：125mg 申请事项：药品注册（境内生产） 注册分类：化学药品 3 类 上市许可持有人：浙江尔婴药品有限公司 1 本次获得对乙酰氨基酚栓《药品注册证书》，标志着尖峰药业及子公司尔 婴公司具有进行该药品生产、销售的资格，将进一步丰富公司医药板块 的产品线，有助于提升公司医药业务的竞争力。 风险提示：由于医药产品具有高科技、高风险、高附加值的特点，不仅 药品的前期研发及研制、报批到投 ...

证券代码：600668 证券简称：尖峰集团 编号：临 2024-001 浙江尖峰集团股份有限公司 关于子公司撤回药品注册申请的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 截至本公告日，已有湖北东信药业有限公司、哈药集团制药总厂、马应龙药 业集团股份有限公司、山东达因金控儿童制药有限公司、湖北潜江制药股份有限 公司等 28 家公司的对乙酰氨基酚栓在中国注册上市。 近日，浙江尖峰集团股份有限公司（以下简称"本公司"）的控股子公司浙 江尔婴药品有限公司（以下简称"尔婴公司"） 收到国家药品监督管理局关于尔 婴公司主动撤回对乙酰氨基酚栓（规格：75mg）注册申请的《药品注册申请终止 通知书》。现将有关情况公告如下： 一、药品基本情况 药品名称：对乙酰氨基酚栓 剂型：栓剂 申请分类：仿制药申请 规格：75mg 注册分类：化学药品 3 类 申请人：浙江尔婴药品有限公司 受理号：CYHS2201184 国 审批结论：根据《药品注册管理办法》第八十九条以及申请人的撤回申请， 1 本次尔婴公司撤回对乙酰氨基酚栓（规格：75mg） ...